Saturday 17 October 2026
Export PLUR’s income statement to Excel — free account
Pluri Inc.
PLUR Healthcare Biotechnology
Pluri Inc.’s revenue for fiscal 2026 (year ended June 2026) was $1.0 million, down 24.0% from fiscal 2025. In the quarter to June 2026, revenue fell 15.8%, EPS grew 48.0%, free cash flow grew 25.0% and total debt rose 3.43%, each against the same quarter a year earlier.
0.93
0.01
−1.06%
Follow PLUR
| Jun '26 | Jun '25 | Jun '24 | Jun '23 | Jun '22 | Jun '21 | Jun '20 | Jun '19 | Jun '18 | Jun '17 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
1 | 3 | 4 | — | — | — | 4 | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
20.04 | 23.48 | 92.58 | 102.18 | 128.98 | — | 2,089.09 | 699.65 | 45.69 | — |
Altman Z-Score |
(30.41) | (17.73) | (15.39) | (11.44) | (8.09) | — | 3.51 | (9.43) | (2.47) | — |
Altman Z″-Score (non-manufacturers) |
(74.67) | (42.95) | (33.86) | (24.17) | (16.04) | — | (6.66) | (27.53) | (17.05) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
P/Operating CF |
(4.58) | (6.01) | (7.00) | (10.12) | (4.70) | — | (25.44) | (10.90) | (22.87) | — |
Beneish M-Score |
(4.29) | 1.41 | (3.58) | (3.31) | — | — | 0.44 | (2.78) | — | — |
P/B ratio |
0.00 | 0.00 | 5.57 | 1.92 | 1.23 | — | 2.87 | 3.33 | 4.64 | — |
Price to Tangible BV |
0.00 | 0.00 | 5.57 | 1.92 | 1.23 | — | 2.87 | 3.33 | 4.64 | — |
EV/Sales |
40.12 | 46.83 | 75.50 | 45.44 | 19.28 | — | 1,507.87 | 465.06 | 35.13 | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
EV/Operating CF |
(2.08) | (3.44) | (1.37) | (0.57) | (0.16) | — | (4.40) | (1.64) | (4.76) | — |
EV/FCF |
(2.02) | (3.16) | (1.34) | (0.56) | (0.16) | — | (4.36) | (1.63) | (4.68) | — |
Quick Ratio |
0.24 | 0.66 | 6.80 | 7.29 | 8.40 | 5.82 | 6.00 | 3.16 | 3.68 | 5.12 |
Current Ratio |
0.27 | 0.68 | 6.98 | 7.37 | 8.46 | 5.85 | 6.07 | 3.23 | 3.75 | 5.36 |
Net Debt/EBITDA |
(0.83) | (0.29) | 0.28 | 0.61 | 0.83 | 0.83 | 1.60 | 0.73 | 0.96 | 1.03 |
Debt/Assets |
113.45% | 70.55% | 60.79% | 47.56% | 32.76% | 26.18% | 2.42% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
(1.62) | (31.55) | 4.44 | 1.58 | 0.69 | 0.43 | 0.03 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.03 | 0.03 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.82 | 0.81 | 0.86 | 0.81 | 0.89 | 0.62 | 0.90 | 0.83 | 0.82 | 0.78 |
Capex/Depreciation |
(1.20) | (5.12) | (1.28) | (0.72) | (0.27) | (0.27) | (0.17) | (0.12) | (0.17) | (0.16) |
Interest Coverage |
(26.76) | (25.40) | (25.59) | (32.32) | (46.89) | (649.01) | (76.76) | (92.29) | (122.21) | (229.66) |
| 260.35% | (992.66%) | (201.67%) | (119.28%) | (92.33%) | (88.06%) | (74.82%) | (140.31%) | (88.93%) | (81.32%) | |
| (74.95%) | (57.75%) | (46.25%) | (47.65%) | (51.04%) | (62.70%) | (60.21%) | (100.49%) | (68.31%) | (66.64%) | |
ROIC |
(526.92%) | (257.19%) | 0.00% | 0.00% | 0.00% | (196.66%) | (162.36%) | 0.00% | 0.00% | (488.34%) |
Return on Tangible Assets |
106.23% | 268.53% | (76.40%) | (77.64%) | (79.84%) | (86.94%) | (67.81%) | (160.12%) | (89.58%) | (90.07%) |
Average Days of Receivables |
31.25 | 64.48 | 38.07 | 670.23 | 2,060.53 | 0.00 | 25,550.00 | 9,604.91 | 6,183.10 | 0.00 |
Research and Development Expense of Revenue |
1,485.43% | 961.90% | 3,817.79% | 5,486.06% | 10,417.52% | 0.00% | 93,813.04% | 48,938.89% | 45,258.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
1,013.68% | 746.93% | 3,077.91% | 4,104.18% | 7,457.26% | 0.00% | 34,443.48% | 16,957.41% | 22,386.00% | 0.00% |
Intangible Assets out of Total Assets |
0.23 | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
366.73% | 160.40% | 803.07% | 1,385.71% | 3,807.26% | 0.00% | 11,139.13% | 9,529.63% | 13,096.00% | 0.00% |
Graham Net Nets |
(1.65) | (0.56) | (0.10) | 0.20 | 0.55 | — | 0.24 | 0.23 | 0.16 | — |
Graham Number |
9.93 | 3.32 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(117.22%) | (72.49%) | (69.83%) | (96.25%) | (104.88%) | — | (18.12%) | (48.82%) | (21.11%) | — |
Free Cash Flow Yield |
(99.20%) | (63.21%) | (60.78%) | (78.84%) | (92.89%) | — | (16.56%) | (40.81%) | (16.41%) | — |
Revenue per Share |
0.10 | 0.21 | 0.06 | 0.06 | 0.06 | 0.00 | 0.01 | 0.04 | 0.04 | 0.00 |
Operating CF per Share |
(2.01) | (2.87) | (3.44) | (4.99) | (9.07) | (8.80) | (11.59) | (19.11) | (16.15) | (19.77) |
Capex per Share |
(0.06) | (0.26) | (0.06) | (0.06) | (0.07) | (0.11) | (0.12) | (0.15) | (0.26) | (0.32) |
Free Cash Flow per Share |
(2.07) | (3.13) | (3.50) | (5.05) | (9.14) | (8.90) | (11.71) | (19.26) | (16.41) | (20.09) |
Cash per Share |
0.80 | 3.32 | 5.77 | 8.83 | 13.92 | 18.65 | 20.37 | 15.83 | 23.11 | 24.40 |
Shareholders Equity per Share |
(1.79) | (0.14) | 1.03 | 3.34 | 8.00 | 16.26 | 24.66 | 14.15 | 21.54 | 27.68 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.79) | (0.14) | 1.03 | 3.34 | 8.00 | 16.26 | 24.66 | 14.15 | 21.54 | 27.68 |
Free Cash Flow |
(20.20) | (19.83) | (18.34) | (23.12) | (36.78) | (31.28) | (26.64) | (29.69) | (21.72) | (21.96) |
Working Capital |
(23.99) | (10.23) | 26.65 | 35.79 | 50.92 | 55.85 | 40.47 | 18.21 | 23.49 | 23.60 |
Capital Expenditures |
(0.61) | (1.62) | (0.32) | (0.26) | (0.28) | (0.37) | (0.27) | (0.24) | (0.34) | (0.35) |
Net Current Asset Value |
(33.58) | (17.45) | (3.00) | 5.91 | 21.87 | 30.98 | 39.03 | 16.88 | 21.58 | 21.73 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
Capex to Sales |
0.61 | 1.21 | 0.99 | 0.91 | 1.20 | 0.00 | 11.74 | 4.43 | 6.84 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | 0.00 | — |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.33 | 0.17 | 0.37 | 0.53 | 1.42 | 0.91 | 0.62 | 0.51 | 0.36 | 0.30 |
Cash ROIC |
(108.48%) | (41.78%) | (30.74%) | (28.94%) | (33.28%) | (21.25%) | (25.61%) | (64.24%) | (36.76%) | (38.58%) |
Accounts Receivable Turnover |
6.29 | 9.90 | 1.16 | 0.31 | 0.17 | 0.00 | 0.02 | 0.05 | 0.05 | 0.00 |
Accounts Payable Turnover |
0.25 | 0.33 | 0.00 | 0.00 | 0.29 | 0.36 | 0.38 | 0.00 | 0.00 | 0.52 |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
1,546.23 | 1,174.74 | 175,838.75 | 118,097.78 | 1,222.56 | 996.16 | 918.08 | 805,555.00 | 1,146,465.00 | 662.10 |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
0.16 | 0.14 | 0.28 | 0.92 | 1.41 | 1.55 | 1.52 | 1.13 | 0.94 | 1.63 |
Average Payables |
2.29 | 2.06 | 2.42 | 3.22 | 3.63 | 3.84 | 4.18 | 5.35 | 5.12 | 4.18 |
Average Assets |
31.78 | 39.11 | 45.16 | 59.43 | 80.80 | 79.54 | 48.42 | 35.14 | 38.25 | 41.74 |
Average Common Equity |
(9.15) | 2.28 | 10.36 | 23.74 | 44.67 | 56.63 | 38.96 | 25.16 | 29.38 | 34.20 |
Columns are period end dates